RedHill Biopharma Announces Positive Top-line Results from YELIVA™ (ABC294640) Phase I Study in Advanced Solid Tumors

TEL-AVIV, Israel, Oct. 26 (Korea Bizwire) — RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” or the “Company”), an Israeli biopharmaceutical company primarily focused on late clinical-stage, proprietary, orally-administered, small molecule drugs for inflammatory and gastrointestinal diseases, including cancer, today announced positive top-line results from the Phase I study with YELIVA™ (ABC294640) in patients with advanced solid [...]